title: [Clinical efficacy of Longidaze for the prevention of cicatricial and sclerotic complications after surgery on the upper urinary tract].
abstract: Results of surgical treatment of patients with ureteral obstruction are not always successful. Prevention of cicatricial and sclerotic complications in the postoperative period plays an important role. In this connection, search for pathogenetic methods that prevent the recurrence of strictures is one of the urgent problems of modern urology. 80 patients, divided into two groups (study and control), each of which was divided into three subgroups depending on the cause and degree of hydronephrosis, were followed-up. The first group consisted of patients with congenital hydronephrosis, the second group consisted of patients who underwent gynecological surgery with development of ureterohydronephrosis as complication. The third group consisted of patients with urolithiasis. All patients received surgical treatment. In postoperative period, active prevention of cicatricial and sclerotic complications in study group of 44 patients was performed. The control group consisted of 36 patients with history of surgery on the upper urinary tract without active antisclerotic prevention in the postoperative period. After interventions on urinary tract, comprehensive postoperative prevention of cicatricial and sclerotic complications using drug Longidaze 3000 IU for 10 injections intramuscularly 1 time every 3 days in combination with magnetic-laser therapy is recommended.
authors.forename: V P
authors.initials: VP
authors.lastname: Avdoshin
authors.forename: T A
authors.initials: TA
authors.lastname: Andriukhin
authors.forename: I V
authors.initials: IV
authors.lastname: Zaĭtseva
authors.forename: T I
authors.initials: TI
authors.lastname: Rusakova
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002921:Cicatrix / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage*; D006869:Hydronephrosis / Q000473:pathology / Q000601:surgery*; D053685:Laser Therapy / Q000379:methods; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000473:pathology / Q000517:prevention & control*; D012598:Sclerosis; D014517:Ureteral Obstruction / Q000473:pathology / Q000601:surgery*; D013520:Urologic Surgical Procedures / Q000009:adverse effects*
chemical_list: D006821:Hyaluronoglucosaminidase